---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-020595"
form_type: "8-K"
ticker: "VVOS"
cik: "0001716166"
company_name: "Vivos Therapeutics, Inc."
filed_at: "2023-06-08T23:59:59+00:00"
generated_at: "2026-06-14T05:07:51.375265+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vivos Q1 revenue up 6% to $3.9M; operating expenses cut 20%; net loss narrows

## Summary
- Revenue $3.9M (+6% YoY); gross margin 61% vs 70% on higher VIP training costs.
- Operating expenses fell 20%; net loss reduced with $3.2M non-cash derivative gain.
- VIP enrollments 38 (+19% YoY); VIP revenue $1.3M (+42%). Cash $7.0M.
- Acquired AFD patents/TMD-Bruxism products; POD study showed 92% migraine resolution.
- Targeting positive cash flow in Q1 2024; multiple DSO/DME pilots underway.

## SEC filing metadata
- accession: 0001493152-23-020595
- form_type: 8-K
- ticker: VVOS
- cik: 0001716166
- company_name: Vivos Therapeutics, Inc.
- filed_at: 2023-06-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716166/000149315223020595/0001493152-23-020595-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716166/000149315223020595/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-020595
- JSON: https://secwatch.observer/filing/0001493152-23-020595.json
- Plain text: https://secwatch.observer/filing/0001493152-23-020595.txt

## Key facts
- Earnings Releases
  Vivos Therapeutics, Inc. reported first quarter ended March 31, 2023 results: revenue $3.9 million.
  - Period: first quarter ended March 31, 2023
  - Revenue: $3.9 million
  - Result: reported results
  source text: Revenue was $3.9 million for the first quarter of 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716166/000149315223020595/0001493152-23-020595-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.